Index of artpub/2021/271916/

Ariceta Iraola, Gema
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
2021
https://ddd.uab.cat/record/271916